Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;41(3):739-48.
doi: 10.3233/JAD-132516.

Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment

Affiliations

Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment

Montserrat Alegret et al. J Alzheimers Dis. 2014.

Abstract

Background: There is a range of factors that predict the development of Alzheimer's disease (AD) dementia among patients with amnestic mild cognitive impairment (MCI).

Objectives: To identify the neuropsychological, genetic, and functional brain imaging data that best predict conversion to AD dementia in patients with amnestic MCI.

Methods: From an initial group of 42 amnestic MCI patients assessed with neurological, neuropsychological, and brain SPECT, 39 (25 converters, 14 non-converters) were followed for 4 years, and 36 had APOE ε4 genotyping. Baseline neuropsychological data and brain SPECT data were used to predict which of the MCI patients would develop dementia by the end of the 4 years of observation.

Results: The MCI patients who had converted to AD dementia had poorer performance on long-term visual memory and Semantic Fluency tests. The MCI subjects who developed dementia were more likely to carry at least one copy of the APOE ε4 allele (Hazard Risk = 4.22). There was lower brain perfusion in converters than non-converters, mainly in postcentral gyrus. An additional analysis of the SPECT data found differences between the MCI subjects and controls in the posterior cingulate gyrus and the basal forebrain. When the brain imaging and neuropsychological test data were combined in the same Cox regression model, only the neuropsychological test data were significantly associated with time to dementia.

Conclusion: Although the presence of reduced brain perfusion in postcentral gyrus and basal forebrain indicated an at-risk condition, it was the extent of memory impairment that was linked to the speed of decline from MCI to AD.

Keywords: Alzheimer's disease; brain SPECT; cerebral perfusion; four-year follow-up; longitudinal; mild cognitive impairment; prospective; visual memory.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Basal low blood flow on the right superior parieto-occipital lobe, right postcentral gyrus, left inferior frontal cortex, left superior parietal lobe, and bilateral precuneus associated with conversion to AD in amnestic MCI subjects. At the top, T-map was represented onto a glass brain in three orthogonal planes, called MIP (maximum intensity projection). At the bottom, T-map was superimposed on the canonical single-subject MR image of SPM8, for a better anatomical location. The colored scale represents statistical values (T-map), showing statistically significant lower brain perfusion in the converter MCI group than in the non converter MCI group (p< 0.01, extent threshold 30 voxels).
Figure 2
Figure 2
Regional perfusion defects (Controls > MCI > AD) The colored scale represents statistical values (T-map), showing statistically significant lower brain perfusion in the MCI and AD groups compared to the Control group.
Figure 3
Figure 3
Regions showing statistically significant correlation between baseline cerebral perfusion and performance on visual recall in all MCI subjects. The colored significant areas (X, Y, Z) are located in Brodman’s Areas 7, 9, 18 and 19 (right) and 11 (left).

References

    1. Ritchie CW, Ritchie K. The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease. BMJ Open. 2012;2:e001893. - PMC - PubMed
    1. Morris JC. Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord. 2005;19:163–165. - PubMed
    1. Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–216. - PMC - PubMed
    1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K Carrillo MC, Thies B, Morrison-Bogarad M, Wgster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–292. - PMC - PubMed
    1. Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, de Leon MJ, Doty RL, Stern Y, Pelton GH. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer’s disease. Biol Psychiatry. 2008;64:871–879. - PMC - PubMed

Publication types

MeSH terms

Substances